ERNA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.0M
-27.1%
4.1M
-26.6%
5.6M
+167.0%
2.1M
+5.1%
2.0M
R&D
1.9M
-33.0%
2.8M
+45.8%
1.9M
+183.3%
676.0K
-34.7%
1.0M
SG&A
1.1M
-14.7%
1.3M
-19.6%
1.6M
+15.0%
1.4M
+48.0%
958.0K
Operating Income
-2990000
+27.1%
-4104000
+26.6%
-5590000
-167.0%
-2094000
-5.1%
-1993000
EBITDA
-2980000
+27.2%
-4095000
-15.7%
-3538000
-87.9%
-1883000
+4.7%
-1976000
Net Income
-2941000
+26.6%
-4009000
+27.2%
-5506000
-266.6%
-1502000
-21.1%
-1240000
EPS (Basic)
$-1.89
+44.4%
$-3.40
+51.1%
$-6.95
-52.4%
$-4.56
-21.0%
$-3.77
EPS (Diluted)
$-1.89
+44.4%
$-3.40
+51.1%
$-6.95
-52.4%
$-4.56
-21.0%
$-3.77
Shares (Diluted)
1.6M
+31.9%
1.2M
+49.4%
792.0K
+139.2%
331.1K
+0.6%
329.0K
Ernexa Therapeutics (ERNA) — Financials